Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,664 across all filing types
Latest filing 2023-10-16 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Anteris Completes DurAVR THV EFS Enrolment 2 pages 246.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 17 October 2023 from Anteris Technologies Ltd reporting the completion of enrolment in an FDA approved Early Feasibility Study (EFS) for their DurAVR™ THV medical device. The content focuses on clinical trial progress, investigator comments, and company statements about the study's significance and next steps. There are no financial statements, earnings data, regulatory certifications, or detailed management analysis. The document is a corporate announcement about a clinical trial milestone rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a company announcement about a clinical development milestone, which aligns best with a general Regulatory Filings (RNS) category as a miscellaneous announcement that does not fit other specific categories.
2023-10-16 English
R&D Refund 2 pages 237.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 13 October 2023, reporting that Anteris Technologies Ltd received a $1.4 million R&D tax refund for the year ended 31 December 2022. The content is brief, focused on the receipt of a government tax incentive refund, and does not contain financial statements, detailed financial performance, or management discussion. It is a specific update on a financing-related event (receipt of a tax refund) rather than a full financial report or earnings release. The document length is short (2903 characters), and it is an announcement of a financial event rather than a detailed report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-10-12 English
Notification of cessation of securities - AVR 5 pages 25.7KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of certain options (securities) for Anteris Technologies Ltd. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement about changes in the company's issued securities, specifically the cessation of certain options. It does not contain financial statements, management discussion, or detailed financial data. It is not a report but an official notification regarding securities status changes. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-10-05 English
Application for quotation of securities - AVR 8 pages 30.6KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary shares. It includes specifics about the number of securities, issue dates, and classifications of securities. This is a formal announcement related to capital changes, specifically the issuance and quotation of new shares resulting from option exercises. It does not contain financial statements, management discussion, or audit information. Therefore, it fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other types of filings.
2023-09-28 English
Cleansing Notice 2 pages 235.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an ASX announcement dated 29 September 2023 regarding the issuance of 1,000 new fully paid ordinary shares due to the conversion of unlisted options. It references compliance with the Corporations Act 2001 and provides details about the securities issued. The document is short (3742 characters) and primarily serves as a notice of a share issue event without detailed financial statements or analysis. It does not contain a full financial report or earnings data but rather an update on capital structure changes. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2023-09-28 English
Change of Director's Interest Notice x 4 11 pages 374.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings and interests of company directors, including the number and class of securities held before and after changes, dates of changes, and nature of changes such as options issued following shareholder approval. The document is a formal notification of personal share transactions by company directors. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. Therefore, it fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades).
2023-09-19 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.